Ankylosing Spondylitis (AS) Market Size & Share, Market Trends and Epidemiology Inisghts

 Ankylosing spondylitis (AS) is a chronic immune-mediated inflammatory arthritis included in the group of spondyloarthritis (SpA). It is also called as Bechterew’s disease, a form of arthritis that primarily affects the spine, although other joints may also be involved. The disease causes inflammation of the spinal joints (vertebrae) that can lead to severe, chronic pain and discomfort.

DelveInsight's "Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Ankylosing Spondylitis, historical and forecasted epidemiology as well as the Ankylosing Spondylitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geography Covered

·         The United States

·         EU5 (Germany, France, Italy, Spain, and the United Kingdom)

·         Japan

Study Period: 2017-2030

View report: https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-market

Ankylosing Spondylitis Disease Understanding and Treatment Algorithm

Ankylosing spondylitis has no known specific cause, though genetic factors seem to be involved. In particular, people who have the HLA-B27 gene are at increased risk of developing ankylosing spondylitis. However, the HLA-B27 allele accounts for only 20% of the genetic effect. Besides, other alleles, especially HLA-B, are thought to play an essential role in the disease.

Based on severity, AS is classified as mild or early AS (stable AS) and severe or advanced AS (active). Early AS usually starts with dull pain in the lower back and the back stiffness, whereas severe AS is associated with continuous inflammation that leads to scarring and permanent damage. Early diagnosis can be difficult but is important; magnetic resonance imaging of the sacroiliac joints can be helpful in early disease

The DelveInsight Ankylosing Spondylitis market report gives a thorough understanding of the Ankylosing Spondylitis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Ankylosing Spondylitis Epidemiology  

Ankylosing spondylitis is considered to be more prevalent in men as compared to women.

The Ankylosing Spondylitis epidemiology division provide insights about historical and current Ankylosing Spondylitis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

DelveInsight’s estimates suggest that there were 1,389,116 prevalent cases of AS in 2017 in the 7MM, and these prevalent cases are expected to increase further during the study period, 2017–2030.

Request for sample pages: https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-market

Ankylosing Spondylitis Drug Chapters

The dynamics of the Ankylosing Spondylitis market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2020–2030. Tofacitinib (Pfizer), Bimekizumab (UCB Biopharma), Filgotinib (Galapagos NV), Tildrakizumab (Sun Pharmaceuticals/Merck and Co.), Upadacitinib (Abbvie) and KHK4827 (Kyowa Kirin) are currently under development for the treatment of AS.

Drug chapter segment of the Ankylosing Spondylitis report encloses the detailed analysis of Ankylosing Spondylitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Ankylosing Spondylitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Ankylosing Spondylitis Market Outlook

Treatment goals of AS are alleviation of pain, recovery of physical functions related to daily life, occupational activities, and delay of structural damage responsible for physical impairments. 

The most important component of non-drug treatments of Ankylosing spondylitis (AS) is the education of patients and regular exercise. 

Currently, the cure for AS is not available in the market, and the available therapies mainly help to reduce the discomfort, pain, and inflammation caused by Ankylosing Spondylitis. In terms of molecule type, the market can be segregated into small molecules, biologics, and biosimilars.

At present, the therapeutic market size of AS is mainly accounted for by physical therapy, surgery, non-steroidal anti-inflammatory drugs (NSAIDs: ibuprofen, and naproxen), steroids (corticosteroids), disease-modifying anti-rheumatic drugs (DMARDs: methotrexate), and biologics.

The Ankylosing Spondylitis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Ankylosing Spondylitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

According to DelveInsight, Ankylosing Spondylitis market in 7MM is expected to change in the study period 2017-2030.

Click here to download full report

Download free sample pages: https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-market

Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more